The purpose of this prospective study was to estimate the effect of 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using 68Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate). The responses were categorized as major change, minor change, no change, or unknown change. Results: There were 103 patients (82%) with disease detected on 68Ga-PSMA-11 PET. On the basis of the survey results, there were 67 patients (53.2%) withmajor changes in management and 8 patients (6.4%) with minor changes. The proportion of cases resulting in a change in management did not significantly differ by baseline PSA level. In patients with PSA levels below 0.2 ng/dL, 7 of 12 patients had disease detected on 68Ga-PSMA-11 PET, 5 of whom had a major change in management. Conclusion: 68Ga-PSMA-11 PET resulted in a major change in management in 53% of patients with biochemical recurrence. Further studies are warranted to investigate whether PSMA-based management strategies result in improved outcomes for patients.
Bibliographical noteFunding Information:
Thomas A. Hope receives grant support from GE Healthcare and is supported by the Radiological Society of North America and the Department of Radiology and Biomedical Imaging, UCSF. No other potential conflict of interest relevant to this article was reported.
- Biochemical recurrence
- Molecular imaging
- Prostate cancer
- Prostate-specific membrane antigen